Core Insights - Hims & Hers Health, Inc. (HIMS) operates a consumer-first, digitally native healthcare platform that provides personalized care through telehealth, online pharmacy, and subscription services, focusing on chronic conditions like sexual health, hormone health, weight loss, dermatology, and mental health [1] Group 1: Business Model and Services - The company integrates licensed providers, proprietary technology, and cloud pharmacy infrastructure to support recurring treatment for various health conditions [1] - Recently, Hims & Hers has expanded into proactive and preventative care, launching Labs for data-driven testing and a multi-cancer early detection test in collaboration with GRAIL [2] - New offerings include menopause and perimenopause services on the Hers platform and exclusive oral testosterone treatments for men's health [2] Group 2: International Expansion - HIMS has entered Canada through the acquisition of Livewell and expanded its weight loss program to the U.K. [3] - The company announced plans to acquire Eucalyptus to enhance its presence in Europe and expand into Australia and Japan [3] Group 3: Market Performance and Valuation - Hims & Hers shares have decreased by 65.4% over the past year, underperforming the industry decline of 29.1% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.3X, significantly lower than the industry average of 3.8X and its five-year median of 2.7X [10] - The Zacks Consensus Estimate for HIMS' 2026 earnings per share suggests flat performance compared to 2025 [8]

Grail Inc. (NASDAQ:GRAL) is one of the best small-cap stocks with huge growth potential. On February 20, Baird cut the price target on Grail Inc. (NASDAQ:GRAL) to $82 from $113 while maintaining an Outperform rating on the shares. The rating update came after the announcement that its NHS study missed its primary endpoint. 15 Healthiest Countries In Africa A healthcare professional wearing a health communications device discussing patient data with a colleague. The same day, Canaccord also cut the price ...

Key Takeaways Hims & Hers is expanding into weight care, menopause, testing and new global markets.Hims & Hers is investing in AI, diagnostics and acquisitions to scale its platform.AMWL is refocusing on enterprise clients, cutting costs and targeting positive cash flow by 2026.Digital healthcare continues to evolve across both direct-to-consumer and enterprise channels, with Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL) , popularly known as Amwell, representing two distinct approache ...

Grail (NASDAQ: GRAL) stock rose by more than 16% by midday. The move follows a couple of days of brutal declines after the release of top-line results from its three-year, 142,000-person trial of its Galleri multi-cancer early detection (MCED) test with England's National Health Service. What went wrong for Grail I discussed the stock's decline on the first day of trading after the release, and the market punished it again on Monday. However, let's focus on why the market may be optimistic about future dev ...

Shares of cancer-detection firm Grail (NASDAQ: GRAL) fell by half in last Friday's trading session. That's quite a turnabout after the company's share price more than quintupled in 2025, from about $19 a share in January to $110 in November. Last week shares of the California-based biotech were trading at around $102. Today they're priced at $49. What happened? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" ...

Grail (NASDAQ: GRAL) stock came under even more pressure today, declining by more than 16% by 12:40 a.m. The move comes as the market continues to digest the unpalatable news that hit the market on Friday. The news wasn't good, but there is a pathway to recovery, however tenuous it might appear now. What happened to Grail stock recently I discussed the game-changing event on Friday. Simply put, the company's trial of its Galleri multi-cancer early detection (MCED) with England's National Health Service (N ...

On February 17, 2026, Baker Bros. Advisors disclosed a purchase of 455,208 shares of GRAIL (NASDAQ:GRAL), an estimated $39.33 million trade based on quarterly average pricing. What happened According to a recent SEC filing dated February 17, 2026, Baker Bros. Advisors increased its position in GRAIL by 455,208 shares. The estimated transaction value, based on the average unadjusted closing price during the fourth quarter of 2025, was $39.33 million. The quarter-end value of the position rose by $82.09 mi ...

2026年2月23日，Mirxes（觅瑞）宣布其CADENCE-CRC结直肠癌早筛研究迎来重大突破。据公告，这 项结直肠癌早筛注册临床试验，招募了6000多名受试者，是东南亚首个、且最大规模的基于血液筛查的 前瞻性研究，覆盖华裔、马来裔、印度裔等多个主要族群。 值得关注的是，就在这一消息发布前不久，美国多癌早筛公司GRAIL（NASDAQ：GRAL）公布了14万 人多癌临床研究的失败结果，引发2月20日股价腰斩，暴跌50%，市场对多癌筛查"概念故事"的信心遭 遇重挫。 相较于多癌筛查，觅瑞则一步一个脚印，优先攻克单癌早筛。通过扎实的临床推进，进一步凸显其在单 癌早筛领域的确证性路径和落地能力，或成为资金避险情绪升温下，赛道内确定性较强的一类资产。 公告显示，随着入组工作收官，觅瑞在消化道肿瘤早筛产品线上迈出关键一步。当前研究已进入数据后 期分析阶段，预计主要结果将于2026年内揭晓。按照规划，公司拟于今年中旬在新加坡及部分东南亚市 场先行推出LDT形式服务，并计划年底前提交IVD注册申请，推动产品正式落地。 （一）结直肠癌筛查的 "死结"：明明可以早发现，为什么那么多人放弃？ 结直肠癌发展周期长达 5-10 ...

US Q4 GDP rose +1.4% (q/q annualized), weaker than expectations of +2.8%. The Q4 core PCE price index rose +2.7%, stronger than expectations of +2.6%.Geopolitical risks are bearish for stocks. President Trump on Thursday ramped up pressure on Iran to strike a deal over its nuclear program, saying he thought 10 to 15 days was “pretty much” the “maximum” he would allow for negotiations to continue, and “We’re either going to get a deal, or it’s going to be unfortunate for them.”Stocks initially moved lower on ...

Grail, Corning, Comfort Systems USA, Opendoor, Akamai, and More Market Movers - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and MoreBy [Mack ...